Product How it works Pricing Blog FAQ About Contact
Protalix Biotherapeutics

Protalix Biotherapeutics (NYSE: PLX) revenue

Protalix Biotherapeutics reported revenue of $52.7m for fiscal 2025, 1.2% less than in fiscal 2024 ($53.4m). Since fiscal 2016 its revenue has grown by 473.4%, an average growth of 21.4% a year.

Protalix Biotherapeutics's revenue has fallen for 2 years in a row, and its best year of the last 10 was fiscal 2023. The biggest drop was in fiscal 2021, −39.0%.

Revenue, in millions of US dollars9.2201621.1201734.2201854.7201962.9202038.4202147.6202265.5202353.4202452.72025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$52.7m−1.2%−$5.5m−10.4%
2024$53.4m−18.5%$3.9m7.3%
2023$65.5m+37.5%$10.5m16.0%
2022$47.6m+24.2%−$13.0m−27.3%
2021$38.4m−39.0%−$20.5m−53.4%
2020$62.9m+15.0%$2.7m4.3%
2019$54.7m+59.7%−$10.7m−19.6%
2018$34.2m+62.4%−$19.3m−56.4%
2017$21.1m+129.1%−$34.5m−163.8%
2016$9.2m—−$33.2m−360.5%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Protalix Biotherapeutics revenue compared with its sector

By revenue for its latest fiscal year, Protalix Biotherapeutics ranks 326th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Protalix Biotherapeutics, −1.2%.

RankCompanyRevenueRevenue growth
324thAgios Pharmaceuticals$54.0m48.0%
325thInvivyd$53.4m110.5%
326thProtalix Biotherapeutics$52.7m−1.2%
327thOcular Therapeutix$52.0m−18.5%
328thLexicon Pharmaceuticals$49.8m60.2%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Protalix Biotherapeutics

How much revenue did Protalix Biotherapeutics make in fiscal 2025?
Protalix Biotherapeutics reported revenue of $52.7m for fiscal 2025, compared with $53.4m in fiscal 2024.
How much has the revenue of Protalix Biotherapeutics grown?
Between fiscal 2016 and fiscal 2025 it went from $9.2m to $52.7m: 473.4% more, an average growth of 21.4% a year.
What was the best year for revenue at Protalix Biotherapeutics?
Of its last 10 fiscal years, fiscal 2023, with $65.5m.
Where does Protalix Biotherapeutics rank in its sector by revenue?
It ranks 326th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Protalix Biotherapeutics come from?
From the annual report (Form 10-K) that Protalix Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Protalix Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Protalix Biotherapeutics: the Protalix Biotherapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.